| 1. | | Recruiting | Randomized Study of Picibanil Sclerotherapy in Children With Macrocystic Lymphangioma
Conditions: Lymphatic Diseases; Lymphangioma; Cardiovascular Abnormalities |
| 2. | | Recruiting | Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease; Lymphatic Disease; Lymphoproliferative Disorder |
| 3. | | Recruiting | Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease; Lymphatic Disease; Lymphoproliferative Disorder; Canale-Smith Syndrome |
| 4. | | Recruiting | Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
Conditions: Lymphoproliferative Disorders; Lymphoma |
| 5. | | Recruiting | Study of TRM-1 (TRAIL-R1 monoclonal antibody) in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin |
| 6. | | Recruiting | Tipifarnib versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Conditions: Myeloid Leukemia; Acute Disease |
| 7. | | Recruiting | Fludarabine, Low-Dose Total-Body Irradiation, Donor Stem Cell Transplantation, and Immunosuppression Therapy in Treating Patients Who Have Fanconi’s Anemia
Conditions: Fanconi's Anemia; adult acute myeloid leukemia; childhood acute myeloid leukemia; Graft Versus Host Disease; Myelodysplastic Syndromes |
| 8. | | Recruiting | Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
Conditions: recurrent adult Hodgkin's lymphoma; recurrent adult Burkitt's lymphoma; post-transplant lymphoproliferative disorder; ... |
| 9. | | Recruiting | PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: adult acute myeloid leukemia with 11q23 (MLL) abnormalities; adult acute myeloid leukemia with inv(16)(p13;q22); ... |
| 10. | | Recruiting | Anti-Thymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplantation for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Graft Versus Host Disease; secondary acute myeloid leukemia |
| 11. | | Recruiting | Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; secondary acute myeloid leukemia |
| 12. | | Recruiting | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; Myelodysplastic Syndromes |
| 13. | | Recruiting | Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; secondary acute myeloid leukemia |
| 14. | | Recruiting | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
Condition: Lymphoma, Follicular |
| 15. | | Recruiting | Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients with Follicular Lymphoma
Condition: Non-Hodgkins Lymphoma |
| 16. | | Recruiting | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma
Conditions: Cutaneous T-Cell Lymphoma; Sezary Syndrome; Mycosis Fungoides |
| 17. | | Recruiting | Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; secondary acute myeloid leukemia |
| 18. | | Recruiting | CpG 7909 in Treating Patients With Cutaneous T-Cell Lymphoma
Conditions: Cutaneous T-Cell Lymphoma; mycosis fungoides and Sezary syndrome |
| 19. | | Recruiting | Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
Conditions: adult non-Hodgkin's lymphoma; adult primary liver cancer; adult solid tumor |
| 20. | | Not yet recruiting | Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma
Conditions: long-term effects secondary to cancer therapy in children; stage I childhood Hodgkin's lymphoma; stage II childhood Hodgkin's lymphoma; ... |
| 21. | | Recruiting | Epoetin alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy
Conditions: adult solid tumor; Anemia; Leukemia; Lymphoma; plasma cell neoplasm |
| 22. | | Recruiting | Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Condition: recurrent adult Hodgkin's lymphoma |
| 23. | | Recruiting | Chemotherapy for Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Solid Malignancies; Non-Hodgkin's Lymphoma |
| 24. | | Recruiting | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: B-Cell Lymphoma; T-Cell Lymphoma |
| 25. | | Recruiting | Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin’s Lymphoma
Condition: Non-Hodgkin's Lymphoma |
| 26. | | Recruiting | Gemcitabine, Dexamethasone and Cisplatin Versus Dexamethasone, Cytarabine, Cisplatin in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Condition: Lymphoma |
| 27. | | Recruiting | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
Conditions: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome |
| 28. | | Recruiting | Cilengitide in Treating Patients With Acute Myeloid Leukemia
Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia |
| 29. | | Recruiting | Motexafin Gadolinium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage II, Stage III, or Stage IV Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: adult non-Hodgkin's lymphoma; indolent or aggressive adult non-Hodgkin's lymphoma |
| 30. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma |
| 31. | | Recruiting | Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: refractory chronic lymphocytic leukemia; noncontiguous stage II small lymphocytic lymphoma; recurrent small lymphocytic lymphoma; ... |
| 32. | | Recruiting | Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer |
| 33. | | Recruiting | Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia |
| 34. | | Recruiting | Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who are Undergoing Donor Stem Cell Transplantation
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Graft Versus Host Disease; hematopoietic and lymphoid cancer |
| 35. | | Recruiting | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplantation for Hematologic Cancer
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Graft Versus Host Disease; hematopoietic and lymphoid cancer |
| 36. | | Not yet recruiting | FR901228 in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Acute Myeloid Leukemia
Conditions: adult acute myeloid leukemia; refractory chronic lymphocytic leukemia; Small Lymphocytic Lymphoma |
| 37. | | Not yet recruiting | Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Lymphoma
Conditions: stage I adult diffuse large cell lymphoma; stage II adult diffuse large cell lymphoma |
| 38. | | Recruiting | 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer |
| 39. | | Recruiting | Thymoglobulin to Prevent Acute Graft vs. Host (GvHD) in Patients with Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
Conditions: Acute myelogenous leukemia (AML); Acute lymphocytic leukemia (ALL); Graft vs. Host Disease (GvHD) |
| 40. | | Recruiting | Phase 3 BBR 2778 for Relapsed, Aggressive Non-Hodgkin’s Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin |
| 41. | | Recruiting | PTK 787 and Gleevec in Patients with AML, AMM, and CML-BP
Conditions: Acute Myelogenous Leukemia; Agnogenic Myeloid Metaplasia; Chronic Myelogenous Leukemia |
| 42. | | Recruiting | Clofarabine alone versus Clofarabine in Combination with Low-Dose Cytarabine (ara-C) in Previously Untreated Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome |
| 43. | | Recruiting | Oral Enzastaurin HCl in Patients with Relapsed Mantle Cell Lymphoma
Condition: Mantle-Cell Lymphoma |
| 44. | | Recruiting | STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients with Hematologic Malignancies
Conditions: Hematological Malignancies; Leukemia; Lymphoma |
| 45. | | Recruiting | Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Conditions: adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia; indolent or aggressive adult non-Hodgkin's lymphoma |
| 46. | | Recruiting | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; childhood acute myeloid leukemia and other myeloid malignancies; ... |
| 47. | | Recruiting | Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma |
| 48. | | Recruiting | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Conditions: recurrent adult diffuse large cell lymphoma; recurrent mantle cell lymphoma; recurrent grade 3 follicular lymphoma |
| 49. | | Recruiting | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions: refractory chronic lymphocytic leukemia; recurrent adult diffuse large cell lymphoma; recurrent adult Hodgkin's lymphoma |
| 50. | | Recruiting | Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Conditions: stage I adult Hodgkin's lymphoma; stage II adult Hodgkin's lymphoma |
